Pancreatic Cancer Research

ResearcherYale Cancer CenterActive in the last 2 years

Charles H. Cha

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7443-1258; OpenAlex author ID A5057178324. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 7

  1. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial. Co-author DOI 10.1001/jamaoncol.2024.1575↗
  2. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0250539↗
  3. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  4. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  5. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2016.45↗
  6. Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. Co-author DOI 10.1038/srep22996↗
  7. The novel tumor angiogenic factor, adrenomedullin-2, predicts survival in pancreatic adenocarcinoma. Last author DOI 10.1016/j.jss.2014.11.002↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jill Lacy · 3 shared papers, 2016–2024 · strength 0.31
  2. Ronald R. Salem · 3 shared papers, 2015–2024 · strength 0.26
  3. John W. Kunstman · 2 shared papers, 2021–2024 · strength 0.26
  4. Xiaojia Guo · 3 shared papers, 2015–2021 · strength 0.25
  5. Stacey Stein · 2 shared papers, 2016–2024 · strength 0.19
  6. Fred S. Gorelick · 2 shared papers, 2016–2021 · strength 0.17
  7. Gary V. Désir · 2 shared papers, 2016–2021 · strength 0.17
  8. Michael Cecchini · 1 shared paper, 2024 · strength 0.14
  9. Guoping Cai · 1 shared paper, 2024 · strength 0.14
  10. Luisa F. Escobar‐Hoyos · 1 shared paper, 2024 · strength 0.14
  11. Mandar Deepak Muzumdar · 1 shared paper, 2024 · strength 0.14
  12. Kimberly L. Johung · 1 shared paper, 2024 · strength 0.14
  13. Adham Adel Jurdi · 1 shared paper, 2024 · strength 0.14
  14. Kenneth Reed Shroyer · 1 shared paper, 2024 · strength 0.14
  15. Lindsay L. Hollander · 2 shared papers, 2015–2016 · strength 0.13
  16. Melena D. Bellin · 1 shared paper, 2021 · strength 0.12
  17. Yasheen Gao · 1 shared paper, 2021 · strength 0.12
  18. William G. Hawkins · 2 shared papers, 2017–2019 · strength 0.11
  19. Andrew H. Ko · 2 shared papers, 2017–2019 · strength 0.11
  20. Brian G. Czito · 2 shared papers, 2017–2019 · strength 0.11
  21. Mahmoud M. Al-Hawary · 2 shared papers, 2017–2019 · strength 0.11
  22. Noelle K. LoConte · 2 shared papers, 2017–2019 · strength 0.11
  23. Sushanth Reddy · 2 shared papers, 2017–2019 · strength 0.11
  24. Efrat Dotan · 2 shared papers, 2017–2019 · strength 0.11
  25. Robert A. Wolff · 2 shared papers, 2017–2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.